To assess whether whole-genome sequencing of circulating tumor DNA can detect residual disease and predict recurrence after surgery for stage IA lung adenocarcinoma.
Approach:
Study design: Retrospective study of 42 patients; researchers analyzed 331 blood samples collected during treatment and follow-up.
Testing method: Researchers sequenced each patient’s tumor and matched normal tissue to create an individual genetic fingerprint, then used an AI-supported algorithm to search for matching patterns in blood-derived ctDNA.
Key Findings:
The approach predicted recurrence with 75% sensitivity and 83% specificity.
Of 12 patients with recurrence, nine had detectable ctDNA.
For six patients, a positive ctDNA result preceded clinical or imaging confirmation by a median of 16.7 months.
Whole-genome sequencing also helped distinguish recurrent disease from a second primary lung tumor.
Interpretation:
The study reports that ctDNA analysis using whole-genome sequencing detected molecular evidence of recurrence before imaging or clinical confirmation in some patients. The authors suggest it could inform postoperative surveillance and identify patients who may benefit from additional treatment.
Limitations:
The study was small and retrospective and requires prospective validation.
Challenges include sample collection, testing costs, and use of routinely processed pathology specimens.
Further studies are needed to determine how molecular monitoring should be integrated with imaging and whether earlier detection improves patient outcomes.
Combining functional laboratory assays with genetic sequencing could help resolve uncertain findings and improve diagnosis of inherited mitochondrial disorders
